MRNA Moderna

Q1 2025 10-Q

Filed: May 1, 2025Period ending Mar 31, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Moderna (MRNA) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• New patent litigation by Arbutus/Genevant filed March 2025 in multiple countries over lipid nanoparticle patents targeting Spikevax and mRESVIA
• Most materially updated risk: PTAB ruling March 2025 found all challenged Moderna patent claims unpatentable in U.S. IPRs, decision subject to appeal

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$108M

▼ -35.3% YoY

Net Income

-$971M

▲ +17.4% YoY

Operating Margin

-972.2%

▼ -21414bp YoY

Net Margin

-899.1%

▼ -19548bp YoY

EPS (Diluted)

$-2.52

▲ +17.9% YoY

Operating Cash Flow

-$1.0B

▼ -4.9% YoY

Source: XBRL data from Moderna Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Moderna Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Moderna

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.